Metsera Inc. (NASDAQ:MTSR) saw a 20% rise in share prices amid a bidding war between Novo Nordisk and Pfizer. Pfizer plans to sue both companies for breaching agreements. Pfizer's discontinued weight loss treatment trial led to the decision to acquire Metsera.